CompuMed, Inc. Hits New 52-Week High at $6.90, Marking Major Milestone

CompuMed, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 6.90 on March 24, 2026. This achievement marks a notable increase from its 52-week low of USD 1.95, showcasing a substantial upward trend in the stock's performance over the past year. Despite being a loss-making entity, CompuMed's stock has demonstrated resilience, with a one-year performance that outpaces the S&P 500 by 13.68%. The company's market capitalization stands at USD 8 million, reflecting its microcap status within the industry. Key financial metrics reveal a price-to-book ratio of 2.56, while the company currently does not offer a dividend yield. Additionally, CompuMed's debt-to-equity ratio is reported at -0.35, indicating a unique financial structure. The return on equity is notably low, reflecting the challenges faced by the company. Overall, CompuMed's recent performance highlights its evolving position in the competitive pharmaceuticals and biotechnology landscape.